Greenness and whiteness profiles of a validated HPTLC method for the simultaneous analysis of clopidogrel and rosuvastatin in fixed-dose combination capsules

The goal of the current work was to create and validate a quick, sensitive, and environmentally friendly reverse-phase “high-performance thin-layer chromatography (HPTLC)” approach for the simultaneous measurement of rosuvastatin (ROS) and clopidogrel (CLOP) in their fixed-dose combination (FDC) capsules. Eight different greenness and whiteness tools, such as the analytical eco-scale (AES), chloroform toxicity (ChlorTox), the analytical GREEnness (AGREE), the modified green analytical procedure index (MoGAPI), the complex MoGAPI, the blue applicability grade index (BAGI), the carbon footprint reduction index (CaFRI), and the click analytical chemistry index (CACI) were utilized to evaluate the method's greenness and whiteness profiles. The suggested strategy was linear for both medications in the 25–1000 ng/band level. The method was proven to be reliable, sensitive, accurate, precise, and eco-friendly. The results of greenness and whiteness tools, such as AES (87), ChlorTox (0.86 g), AGREE (0.72), MoGAPI (85), complex MoGAPI (90), BAGI (77.5), CaFRI (89), and CACI (91) demonstrated that the current method had the unparalleled greenness and whiteness profiles. Using the proposed methodology, it was found that the assay of CLOP and ROS in FDC products A and B was ranged from 98.41 to 101.02%. These results confirm that the suggested approach is appropriate for concurrently analyzing ROS and CLOP. The work's findings showed that the suggested approach might be used to consistently analyze CLOP and ROS in commercial dosage forms.